<DOC>
	<DOCNO>NCT00160641</DOCNO>
	<brief_summary>An open end study patient complete precede double-blind study NCT00160602 give Certolizumab Pegol assess sign symptom Rheumatoid Arthritis .</brief_summary>
	<brief_title>A Study Safety Effectiveness Liquid Certolizumab Pegol Treatment Signs Symptoms Rheumatoid Arthritis Prevention Joint Damage Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients must either fail achieve American College Rheumatology 20 % ( ACR20 ) response Weeks 12 14 C87050 [ NCT00160602 ] , must complete entire Week 24 assessment C87050 [ NCT00160602 ] trial . A diagnosis inflammatory Arthritis ( e.g . Psoriatic Arthritis Ankylosing Spondylitis ) A secondary , noninflammatory type Arthritis ( e.g . Osteoarthritis Fibromyalgia ) Investigator 's opinion symptomatic enough interfere evaluation effect CDP870 patient 's primary diagnosis Rheumatoid Arthritis ( RA ) Any concomitant biological therapy Any experimental therapy , within outside clinical</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>CDP870</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>